Interim / Quarterly Report • Sep 2, 2024
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
(Convenience translation originally issued in Turkish)
To the Board of Directors of Fonet Bilgi Teknolojileri A.Ş.
We have reviewed the accompanying interim consolidated statement of financial position of Fonet Bilgi Teknolojileri A.Ş.(the Company) and its subsidiaries (the Group) as of 30 June 2024 and the interim consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and the consolidated statement of cash flows for the six-month period then ended, and a summary of significant accounting policies and other explanatory notes. The Group management is responsible for the preparation and fair presentation of these interim consolidated financial statements in accordance with Turkish Financial Reporting Standards. Our responsibility is to express a conclusion on these interim consolidated financial statements based on our review.
We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review of interim financial information is substantially less in scope than an audit conducted in accordance with Independent Auditing Standards and the objective of which is to express an opinion on the financial statements. Consequently, a review of the consolidated interim financial information does not provide assurance that the audit firm will be aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at 30 June 2024, and its consolidated financial performance and its consolidated cash flows for the six-month period then ended in accordance with Turkish Financial Reporting Standards.
EREN Bağımsız Denetim A.Ş. Member Firm of Grant Thornton International
Nazım Hikmet Sorumlu Ortak Baş Denetçi
İstanbul, 2.09.2024
01 January 2024 – 30 June 2024
"Strong Accumulation Innovative Technology"
| I. | ABOUT US3 |
|
|---|---|---|
| II. | CAPITAL STRUCTURE4 |
|
| III. | INFORMATION ON PRIVILEGED SHARES5 |
|
| IV. | COMPANY MANAGEMENT AND EMPLOYEE INFORMATION6 |
|
| V. | CORPORATE ACTIVITIES 8 |
|
| VI. | FINANCIAL CONDITION OF THE COMPANY8 |
|
| VII. | STOCK INFORMATION |
10 |
| VIII. | SOURCES OF FINANCE |
11 |
| IX. | AMENDMENTS IN THE COMPANY'S ARTICLES OF ASSOCIATION |
11 |
| X. | BENEFITING FROM THE GOVERNMENT PROMOTIONS |
17 |
| XI. | RESEARCH AND DEVELOPMENT ACTIVITIES |
17 |
| XII. | SUBSIDIARIES AND BRANCHES OF THE COMPANY |
17 |
| XIII. | OTHER ISSUES |
18 |
Fonet Information Technology A.Ş (The Company) is subject to the laws of the Republic of Türkiye, Capital Market Law, and the provisions of the Turkish Commercial Code relating to the establishment of joint stock companies. Therefore, it operates in accordance with the provisions contained in the Turkish Commercial Code and Capital Market Law especially the provisions contained in the articles of association of the company, and on the condition that it stays within the scope of business.
Accordingly, the main business issue of The Company is the "Information Technology Sector" and its activity is defined in detail in Article 3 titled purpose and subject of the articles of association.
| Trade Name | Fonet Bilgi Teknolojileri A.Ş. | |
|---|---|---|
| Establishment Date |
10.01.2001 | |
| Area of Activity | Software/Informatics | |
| Paid – in Capital |
144.000.000 TL | |
| Upper Limit of Registered Capital |
2.500.000.000 TL | |
| Address | Kızılırmak Mahallesi 1445. Sokak No: 2B/1 The Paragon Tower Çankaya / ANKARA |
|
| Phone | +90 312 438 59 19 | |
| Fax | +90 312 440 36 52 | |
| Trade Registry No |
350735 | |
| E-Mail Address | [email protected] | |
| Website | www.fonetbt.com |
FONET; has been founded in 1997 to serve the IT healthcare sector. It is an IT company that turned into a limited liability Corporation in 2001 and then, turned into a joint-stock company in 2011. It gives services turnkey projects in the Healthcare IT field which are related to Information Management Systems, System Integration, and Consultancy services. Despite healthcare information technology being the main activity subject of Fonet, it is also involved in different information technology projects with field expertise.
Within the scope of the transformation in the health sector in our country in the late 90s and early 2000s, we focused on the health sector in line with the use of information
technologies in the health sector and having Health Institutions serving at international standards and started to produce solutions in this context. It follows improving technology and regarding regulations closely and it keeps itself updated. Fonet's aim is to reach all international standards in all hospitals which has been given service by Fonet in the healthcare informatics system field.
Developing advanced technology and also develop. In this way, we contribute to Turkey's economy and we intended to strengthen Turkey's position in the global marketplace.
To be a leader company in its sector that provides development and change with advanced technology in the information sector continuously increases value created for its customers, gives a quality service with knowledge of technology, professional team, entrepreneur, and customer-oriented approach.
The company, which has adopted the registered capital system, has set its registered authorized capital (upper limit) to 2.500.000.000,00 Turkish Liras until the year 2028 along with the permission of the Capital Markets Board.
The company's issued capital is 144.000.000,00 Turkish Liras which has been paid in full within the upper limit of registered capital.
The company started to be traded in Istanbul stock on May 04, 2017. Details of the shares that form the capital of the company, which has started trading in the BIST ALL SHARES-100 / BIST ALL SHARES/ BIST INFORMATICS / BIST TECHNOLOGY / BIST ANKARA / BIST PARTICIPATION ALL / BIST 500 / BIST MAIN markets, are as shown in the table below;
| SHAREHOLDER | SHARE IN CAPITAL (TL) | RATIO IN CAPITAL (%) | VOTING RIGHT RATIO (%) |
|---|---|---|---|
| ABDÜLKERİM GAZEN | 55.217.999,16 | 38,35 | 65,32 |
| OTHER | 88.782.000,84 | 61,65 | 34,68 |
| TOTAL | 144.000.000,00 | 100 | 100 |
Each share in the General Assembly has 15 Voting Rights. If the company's Board of Directors consists of five members, two board members; consists of six or seven members, three board members; consists of eight or nine members, four board members of the Board of Directors (A) are elected by the General Assembly among the candidates to be determined by the shareholders.
If the shareholders of the group (A) does not nominate to the Board of directors, the election shall be held by the General Assembly within the framework of the Capital Markets legislation and the provisions of the Turkish commercial code.
Group (A) shares have the privilege to determine the members of the Board of Directors and also have the right to vote in the General Assembly.
Group (B) shares have no privileges.
Articles of Association Article 10:
At Ordinary and Extraordinary General Assembly Meetings (A) group shareholders have 15 voting rights for each share, (B) group shareholders have 1 voting rights for each one share.
The management and representation of the Company belong to the Board of Directors. The business and administration of the Company is carried out by 6 Members of the
Board of Directors elected by the General Assembly in accordance with the provisions of the Turkish Commercial Code. Members of the Board of Directors can be elected for a maximum of 3 years. The Board of Director Members whose term of office expires can be elected again.
The chairman of the Board of Directors is elected by the members of the Board of Directors that the (A) group of shareholders offer. The Members of The Board of Directors can also be The Members of The Board of Directors of the other companies.
The Members of The Board of Directors do not have activities within the scope of Prohibition of competing with the company through transactions on behalf of the company, itself, or others.
| NAME & SURNAME | ROLE | DUTY TERM |
|---|---|---|
| Abdülkerim GAZEN | Chair | 03.04.2022 - 29.03.2025 |
| Yasemin ŞAH | Vice Chair | 03.04.2022 - 29.03.2025 |
| Dr. Emre SEZGİN | Member | 03.04.2022 - 29.03.2025 |
| Daniel Anders Henrik WERNER | Member | 03.04.2022 - 29.03.2025 |
| Nisabeyim GAZEN | Member | 03.04.2022 - 29.03.2025 |
| Prof. Dr. Muhammet Ali AKCAYOL | Independent Member | 10.05.2023 – 10.05.2026 |
| Dr. Ali ÖZÖN | Independent Member | 10.05.2023 – 10.05.2026 |
In order for the Board of Directors to perform its duties and responsibilities in a sound manner, Pursuant to Article 4.5 of the corporate governance communiqué no: II-17.1 of the Capital Markets Board, the Board of Directors has decided to create the "Audit Committee", "Early Detection of Risk Committee" and "Corporate Governance Committee" and determine job definitions; The board of Directors has decided not to establish a different "Nomination Committee" and "Compensation Committee", in place of this regarding committee's duties have been undertaken by the "Corporate Governance Committee".
The audit committee supervises the company's accounting system, public disclosure of financial information, independent audit, and the functioning and effectiveness of the company's internal control and internal audit system.
| NAME & SURNAME | ROLE | TITLE |
|---|---|---|
| Prof. Dr. Muhammet Ali AKCAYOL | Chairman of the Audit Committee | Independent Board Member |
| Dr. Ali ÖZÖN | Member of the Audit Committee | Independent Board Member |
Early Detection of Risk Committee; it is responsible for early identification of risks that may endanger the existence, development and continuation of the company, taking necessary measures regarding the identified risks, and carrying out activities to manage the risk and it reviews risk management systems. The committee evaluates the situation in its report to the board of directors every two months, points out the dangers, if any, and shows the remedies.
| NAME & SURNAME | ROLE | TITLE |
|---|---|---|
| Dr. Ali ÖZÖN | Early Detection of Risk Committee Chairman | Independent Board Member |
| Dr. Emre SEZGİN | Early Detection of Risk Committee Member | Board Member |
The corporate governance committee determines whether corporate governance principles are applied in the company, if not, its rationale and conflicts of interest that arise from not fully complying with these principles, and advises the board of directors to improve corporate governance practices and it supervises the work of the investor relations department.
| NAME & SURNAME | ROLE | TITLE |
|---|---|---|
| Prof. Dr. Muhammet Ali AKCAYOL |
Corporate Governance Committee Chairman |
Independent Board Member |
| Dr. Emre SEZGİN | Corporate Governance Committee Member |
Board Member |
| Meltem KAVAK | Corporate Governance Committee Member |
Investor Relations Manager |
As of 30th June, 2024, the number of personnel is 498 and the distribution is as follows:
| EMPLOYEE DISTRIBUTION | NUMBER | |
|---|---|---|
| Administrative Staff | 13 | |
| R&D Staff |
128 | |
| Company Headquarters Total | 141 | |
| Techinical Staff * | 357 | |
| Total | 498 |
* Within the scope of the contracts, they are the personnel working in the hospitals related to the fixed-term employment contract.
In the relevant accounting period, there is no legal action taken for the benefit of the company, its parent company and its subsidiary, or its subsidiary with the guidance of the parent company, or any measures taken or avoided for the benefit of the parent partner or its subsidiary.
In the relevant accounting period, all of the commercial activities performed between both its controlling shareholder and its subsidiary were realized in accordance with market conditions. There are no administrative or judicial sanctions imposed on the company and its managers due to practices contrary to the provisions of the law. Detailed information on other activities that are conducted is summarized under "XIII other issues".
Budget objective has been attained.
| 30 June 2024 | 30 June 2023 | |
|---|---|---|
| CONTINUING OPERATIONS | ||
| Revenue | 236.580.580 | 168.556.676 |
| Cost of Sales (-) | -154.040.926 | -115.120.372 |
| GrossProfit(Loss)FromCommercial Operations |
82.539.654 | 53.436.304 |
| General Administrative Expenses (-) | -24.592.291 | -29.458.832 |
| Marketing Expenses (-) | -2.354.011 | -2.068.720 |
| Research and Development Expense (-) | -1.615.217 | -724.916 |
| Other Income from Operating Activities | 44.122.812 | 12.258.796 |
| Other Expenses from Operating Activities (-) | -11.318.082 | -1.980.724 |
| PROFIT (LOSS) FROM OPER. ACTIVITY (-) | 86.782.865 | 31.461.908 |
| Investment Activity Income | 3.615.262 | - |
| Investment Activity Costs | - | -444.552 |
| PROFIT (LOSS) BEF. FIN. INCOME (EXPENSE) | 90.398.127 | 31.017.356 |
| Finance Incomes | 863.383 | 1.355.082 |
| Finance Costs (-) | -3.053.115 | -747.216 |
| Monetary Loss / Gain due to Inflation | -2.605.490 | -7.469.485 |
| PROFIT (LOSS) FROM CONTINUING OPERATIONS, BEFORE TAX |
85.602.905 | 24.155.737 |
| Tax (Expense) Income, Continuing Ops. (-) | -15.180.576 | -17.030.004 |
| Current Income Tax Expense | - | - |
| Deferred Tax (Expense) Income (-) | -15.180.576 | -17.030.004 |
| PROFIT (LOSS) FROM CONTINUING OPS. | 70.422.329 | 7.125.733 |
|---|---|---|
| PROFIT (LOSS) | 70.422.329 | 7.125.733 |
| ASSETS | 30 June 2024 | 31 December 2023 |
|---|---|---|
| Current Assets | 101.696.883 | 52.776.444 |
| Nun-Current Assets | 880.569.475 | 861.683.307 |
| TOTAL ASSETS | 982.266.358 | 914.459.751 |
| LIABILITIES | 30 June 2024 | 31 December 2023 |
| Current Liabilities | 59.229.069 | 64.009.478 |
| Non-Current Liabilities | 12.609.014 | 10.384.307 |
| Equity | 910.428.275 | 840.065.966 |
| LIQUIDITY RATIOS | 30 June 2024 | 31 December 2023 |
|---|---|---|
| Current Ratio | 1,72 | 0,82 |
| Liquid Ratio | 1,72 | 0,78 |
| Cash Ratio | 0,19 | 0,23 |
| FINANCIAL STRUCTURE RATIOS | 30 June 2024 | 31 December 2023 |
| Leverage Ratio | 0,07 | 0,08 |
| Financing Ratio | 12,67 | 11,29 |
| Debt Equity Ratio | 0,08 | 0,09 |
| PROFITABILITY RATIOS | 30 June 2024 | 31 December 2023 |
| Asset Profitability | 0,07 | 0,20 |
| Equity Profitability | 0,08 | 0,22 |
Public Offering Date: 27-28 April 2017 Total Equity: 144.000.000,00 TL (Nominal worth of each share is 1 TL). Free Float Rate: %61,65 StockMarketCode:FONET Code:TREFONT00028
The public offering date of the company's shares is 27-28 April 2017. The shares are started to be traded on Borsa Istanbul as of May 04, 2017. The market price of our company's shares is 17,40 TL as of 30 June, 2024.
The finance sources of the company are its own equity and bank loans.
After obtaining the necessary legal permissions from the Capital Markets Board and the Republic of Turkey Ministry of Trade for the amendment of Article 6 of the Articles of Association of the Company titled "Capital of the Company and Type of Shares" by the Board of Directors of our Company, and after being discussed and resolved at the Ordinary General Assembly Meeting of our Company held on 24.07.2024, it was registered on 26.07.2024 and published in the Turkish Trade Registry Gazette dated 26.07.2024 and numbered 11130.
| Current Version | Amended Version |
|---|---|
| Same as Turkish Trade Registry Gazette dated 27.12.2023 and numbered 10988. |
|
| Company's Capital and Type of Shares: | Company's Capital and Type of Shares: |
| Article 6 | Article 6 |
| The registered capital ceiling of the Company is 400.000.000.- (Four hundred million) Turkish Liras, divided into 400.000.000.- (Four hundred million) shares, each with a nominal value of 1 (One) Turkish Lira. |
The Company has accepted the registered capital system in accordance with the provisions of the Capital Markets Law and has switched to the registered capital system with the permission of the Capital Markets Board dated 27/02/2015 and numbered 5/253. |
| The registered capital ceiling permission granted by the Capital Markets Board is valid for the years 2022-2026 (5 years). At the end of 2026, even if the permitted equity ceiling has not been reached, in order for the board of directors to take a capital increase decision after 2026, it is |
The equity ceiling of the Company is 2.500.000.000.- (two billion five hundred million) Turkish Liras and is divided into 2.500.000.000.000.- (two billion five hundred million) shares each with a nominal value of 1 (One) Turkish Lira. |
| obligatory to obtain authorization from the general assembly for a new period not exceeding 5 years by obtaining permission from the Capital Markets Board for the previously permitted ceiling or a new ceiling amount. If the said authorization is not obtained, no capital increase can be made by the board of directors. |
The equity ceiling permission granted by the Capital Markets Board is valid for the years 2024-2028 (5 years). At the end of 2028, even if the permitted equity ceiling has not been reached, in order for the board of directors to take a capital increase decision after 2028, it is obligatory to obtain authorization from the general assembly for a new period not exceeding 5 years by obtaining permission from |
| The registered capital ceiling permission granted by the Capital Markets Board is valid for the years 2022-2026 (5 years). At the end of 2026, even if the permitted equity ceiling has not been reached, in |
the Capital Markets Board for the previously permitted ceiling or a new ceiling amount. If the said authorization is not obtained, no capital increase can be made by the board of directors. |
| order for the board of directors to take a capital increase decision after 2026; it is obligatory to obtain authorization from the general assembly for a new period not exceeding 5 years by obtaining permission from the Capital Markets Board for the previously permitted ceiling or a new ceiling amount. If the said authorization is not obtained, no capital increase can be made by the Board of Directors. |
The issued capital of the Company is TL 144,000,000 (one hundred and forty-four million) and the said issued capital has been paid in full free of collusion. This capital is divided into 144,000,000 (one hundred and forty-four million) shares with a nominal value of TL 1 (one) each. Of these shares, 8,000,000 (eight million) are Class A registered shares and 136,000,000 (one hundred thirty-six million) are Class B bearer shares. |
| The share capital of the Company is 144,000,000 Turkish Liras. This capital is divided into 144,000,000 shares with a value of 1.00 Turkish Liras each and divided into A and B group shares. |
No new shares may be issued unless the issued shares are fully sold and their consideration is paid or the unsold shares are canceled. Shares representing the capital are monitored in dematerialized form within the framework of |
dematerialization principles.
Group A: 8,000,000 Turkish Liras for 8,000,000 shares,
Group B: 136,000,000 Turkish Liras for 136,000,000 shares,
Total: 144,000,000 Turkish Liras for 144,000,000 shares,
The Company has accepted the registered capital system in accordance with the provisions of the Capital Markets Law and has switched to the registered capital system with the permission of the Capital Markets Board dated 27/02/2015 and numbered 5/253.
The equity ceiling of the Company is 400.000.000.- (Four hundred million) Turkish Liras, divided into 400.000.000.- (Four hundred million) shares, each with a nominal value of 1 (One) Turkish Lira.
The equity ceiling permission granted by the Capital Markets Board is valid for the years 2022-2026 (5 years). At the end of 2026, even if the permitted equity ceiling has not been reached, in order for the board of directors to take a capital increase decision after 2026, it is obligatory to obtain authorization from the general assembly for a new period not exceeding 5 years by obtaining permission from the Capital Markets Board for the previously permitted ceiling or a new ceiling amount. If the said authorization is not obtained, no capital increase can be made by the board of directors.
The issued capital of the Company is TL 144,000,000 (one hundred and forty-four million) and the said issued capital has been paid in full free of collusion.This capital is divided into 144,000,000 (one hundred and forty-four million) shares with a nominal value of TL 1 (one) each.Of these shares, 8,000,000 (eight million) are Class A registered shares and 136,000,000 (one hundred thirty six million) are Class B bearer shares.
No new shares may be issued unless the issued shares are fully sold and their
The capital of the Company may be increased or decreased, if necessary, in accordance with the provisions of the Turkish Commercial Code and Capital Markets Legislation.
Group (A) shares have privileges in determining the members of the board of directors and exercising voting rights in the general assembly. Group (B) shares do not have privileges.
In capital increases, Group (A) shares in proportion to Group (A) shares and Group (B) shares in proportion to Group (B) shares shall be issued to represent the increased capital. In the event that it is decided to issue only Group (B) shares in capital increases through rights issues without restricting the right to acquire new shares, Group (A) shareholders shall be entitled to acquire Group (B) shares in proportion to their shares in the capital. In case of restriction of new share purchase rights, the shares to be issued will be Group (B) shares.
In capital increases, bonus shares are distributed to the existing shares on the date of the increase.
The Board of Directors is authorized to increase the issued capital by issuing (A) group registered shares and/or (B) group bearer shares up to the registered capital ceiling whenever it deems necessary in accordance with the provisions of the Capital Markets Law.
The board of directors may resolve to issue shares above or below the nominal value and to partially or completely restrict the shareholders' rights to acquire new shares or to restrict the rights of privileged shareholders.
The authorization to restrict the right to purchase new shares may not be used in a way to cause inequality among the shareholders. The decisions taken by the board of directors within the scope of this paragraph shall be announced to the public within the framework of the principles determined by the Capital Markets Board.
Explanation regarding privileges:
A total of 8,000,000 shares are privileged.
| consideration is paid or the unsold shares are canceled. Shares representing the capital are monitored in dematerialized form within the framework of dematerialization principles. |
Group (A) shareholders have 15 voting rights for each share and Group (B) shareholders have 1 voting right for each share in the ordinary and extraordinary general assembly meetings of the Company. |
|---|---|
| The capital of the Company may be increased or decreased, if necessary, in accordance with the provisions of the Turkish Commercial Code and Capital Markets Legislation. |
|
| Group (A) shares have privileges in determining the members of the board of directors and exercising voting rights in the general assembly. Group (B) shares do not have privileges. |
|
| In capital increases, Group (A) shares in proportion to Group (A) shares and Group (B) shares in proportion to Group (B) shares shall be issued to represent the increased capital. In the event that it is decided to issue only Group (B) shares in capital increases through rights issues without restricting the right to acquire new shares, Group (A) shareholders shall be entitled to acquire Group (B) shares in proportion to their shares in the capital. In case of restriction of new share purchase rights, the shares to be issued will be Group (B) shares. |
|
| In capital increases, bonus shares are distributed to the existing shares on the date of the increase. |
|
| The Board of Directors is authorized to increase the issued capital by issuing (A) group registered shares and/or (B) group bearer shares up to the registered capital ceiling whenever it deems necessary in accordance with the provisions of the Capital Markets Law. |
|
| The board of directors may resolve to issue shares above or below the nominal value and to restrict the rights of shareholders to acquire new shares partially or completely or to restrict the rights of privileged shareholders. The authority to restrict the |
| rightto buy new shares cannot be used to |
|---|
| cause inequality amang the shareholders. |
| Decisions taken by the Board of Directors |
| within the scope of this clause are |
| announced to the public within the |
| framework of the principles determined by |
| the Capital Markets Board. |
| Explanation regarding privileges: |
| A total of 8000000 shares are privileged. |
| Group (A) shareholders have 15 voting |
| rights for each share and Group (B) |
| shareholders have 1 voting right for each |
| share in the ordinary and extraordinary |
| general assembly meetings of the |
| Company. |
As a result of the evaluation made by the Ministry of Science, Industry and Technology Evaluation and Audit Commission, it was deemed appropriate to certify as R&DCenter. Thus, the company has been entitled to benefit from promotions and exemptions provided to R&D Centers within the scope of Law No. 5746.
Gaining R&D Center status, in addition to the fact that the company creates cost advantages in production activities, will increase cooperation with universities and other R&D institutions, this will clear the way for the company to focus its R&D efforts for the use of innovative and advanced technology and we believe that it will positively contribute to turnover and profitability by creating an important competitive advantage in the markets.
Within the scope of e-Transformation Information Management Systems in Health, e-Insurance Information Management Systems, Personal Health Record Information System and Hospital Information Management System (HIMS) projects running on Java-based Cloud Architecture R&D activities continue.
Pidata Information Technologies Inc. has been founded as a wholly-owned subsidiary by Fonet Information Technologies Inc. in 2018 to develop projects, other than HIMS and to realize other information technology investment targets.
We have three branches in Istanbul, Şanlıurfa and Hacettepe Teknokent and a liaison office in Stockholm, Sweden.
Üniversiteler Mahallesi 1596. Cad. Hacettepe Teknokent 6. Ar-Ge Binası E Blok Kat :5 No:29 Çankaya / ANKARA Phone: +90.312 438 59 19
Büyükdere Cad. Emlak Kredi BloklarıNo:33/4 Levent, İSTANBUL Phone: +90.212 284 18 61 Fax: +90 212 284 18 63
İpekyol Cad. No:12/1 ŞANLIURFA Phone: +90.414 312 72 52 Fax: +90.414 315 76 04
Klarabergsviadukten 70 D4, 111 64 Stockholm Sweden Phone: +46-8-506 36 194
After the end of the activity period, the particular importance issues that realized in the company and that may affect the rights of partners, creditors and other relevant persons and organizations are presented below for your information;
- The Ordinary General Assembly Meeting of our Company for 2023 was held on Wednesday, July 24, 2024, at 10:00, at Kızılırmak Mahallesi 1445. Sokak No: 2B / 18 The Paragon Tower Çankaya / ANKARA.
- Our Company's Ordinary General Assembly Meeting for 2023, held on 24.07.2024, was registered on 26 July 2024 and announced in the Trade Registry Gazette dated 26 July 2024 and numbered 11130.
The company has announced the following developments to the public between 31st March 2024 and 30th June 2024 through the "Public Disclosure Platform" (KAP):
were decided. Our Company has applied to the Capital Markets Board as of today (22.05.2024).
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.